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A B S T R A C T
Purpose: The goal of this study is to report the efﬁcacy and tolerability of lacosamide (LCM)
monotherapy, as ﬁrst-line and conversion regimens, in the treatment of patients with partial-onset
seizures.
Methods: We retrospectively reviewed the charts of patients with focal epilepsy on LCM monotherapy
from six centers in Spain. Efﬁcacy and tolerability were evaluated in the overall group and in subgroups
of patients who were naive to antiepileptic drug (AED) therapy (Group 1) and those who had previously
been treated with AEDs (Group 2).
Results: Sixty-six patients were identiﬁed including 18 patients in Group 1 and 48 patients in Group 2.
Patients were followed up for 0.5–54 months in monotherapy (mean 15.5 months). Forty-two (63.6%)
patients remained seizure-free during all the follow-up. At 6 and 12 months, seizure-free rates were
77.6% and 72.3%, respectively. The drug was withdrawn in 10 (15%) patients (3 side effects, 6 lack of
efﬁcacy, 1 other reason). Fifteen (22.7%) patients reported mild to moderate side effects with the use of
LCM. No differences were found between Groups 1 and 2 regarding efﬁcacy outcomes or tolerability
issues.
Conclusions: In our series more than two-thirds of the patients remained seizure-free on LCM
monotherapy. Side effects were generally mild and led to discontinuation in only 3/66 (4.5%) patients.
Our experience suggests that LCM monotherapy, either as ﬁrst-line or after conversion, may be a
valuable option for patients with focal epilepsy.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Lacosamide (LCM) is an AED initially approved for the
adjunctive treatment of partial-onset seizures in adult patients.
Three double-blind, placebo-controlled trials [1–3] and two long-
term follow-up studies [4,5] have established the clinical efﬁcacy
and safety of the oral formulation of LCM in patients with
pharmacoresistant partial epilepsy. In 2014, a FDA license* Corresponding author at: Epilepsy Unit/Neurology Service, Hospital Universi-
tario Fundacio´n Jime´nez Dı´az, 28040 Madrid, Spain. Tel.: +34 91 550 4854;
fax: +34 91 549 7700.
E-mail address: joseserratosa@me.com (J.M. Serratosa).
http://dx.doi.org/10.1016/j.seizure.2015.04.003
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reextension allowed LCM to be used as monotherapy for the
treatment of partial-onset seizures in patients 17 years of age and
older in the USA while in the European Union LCM has not yet
received EMA approval for its use as monotherapy. A randomized,
historical-controlled, monotherapy conversion trial conducted in
the USA has demonstrated that LCM 400 mg/daily is effective for
the treatment of adult patients with focal epilepsy with a favorable
safety proﬁle [6]. In Europe, a multicentre, randomized mono-
therapy study comparing LCM with sustained release CBZ in
patients with partial-onset seizures is currently underway. So far,
experience with LCM monotherapy in a real-life clinical setting is
sparse and limited to reports of a few patients with conversion to
monotherapy [4,7,8]. In the largest and more recent of these series,served.
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remained seizure free at 6 and 12 months follow-up [8]. However,
no efﬁcacy and tolerability data on the use of LCM as ﬁrst-line
monotherapy are available.
The aim of the present study is to explore the clinical outcome
in patients on LCM monotherapy reached after initial prescription
or after conversion to monotherapy in daily clinical practice.
2. Methods
All patients with partial onset-seizures from six hospitals in
Spain who had been treated with at least one dose of LCM
monotherapy since the introduction of the drug in September 2009
until May 2014 were identiﬁed. Charts were reviewed for patient
demographic and clinical data including age at seizure onset,
maintenance dose, duration of treatment and adverse events. For
the purposes of this analysis patients were divided into two
groups: those with recently diagnosed epilepsy for whom LCM was
their ﬁrst AED (Group 1) and those who reached LCM monotherapy
after discontinuing other AEDs (Group 2). In the latter group we
also recorded the reason for introducing LCM (seizure control or
intolerance to other AEDs), and previous and concomitant
antiepileptic drug therapy. After reviewing clinical data records,
patients with an inaccurate diagnosis of epilepsy, treatment non-
compliance and/or unreliable seizure frequency account were
excluded from the analysis.
According to the participating physicians criteria, a daily dose of
50 or 100 mg of LCM was prescribed initially and titrated to an
optimal maintenance dose for each patient depending on efﬁcacy
and tolerability.
Efﬁcacy was evaluated by analyzing seizure-free rates and
mean seizure frequency reduction during the complete follow-up
and during the ﬁrst 6 and 12 months after reaching the ﬁxed
maintenance dose. Seizure freedom was deﬁned as no seizures on
LCM monotherapy during the evaluated study period (complete
follow-up or 6 and 12 months after reaching the maintenance
dose).
Frequency and types of side effects related to the use of LCM
were recorded. We also studied the one-year retention rate.Table 1
Patient demographics and characteristics.
Demographic and clinical data Total population (n =
Female 37 (56%) 
Mean age, years (range) 49.4 (16–92) 
Mean  SD age at epilepsy onset, years 42.9  21.5 





Simple partial 16 
Complex partial 29 
Secondarily generalized 39 
Median (range) number of seizures
3 month baseline period 2 (0–180) 
12 month baseline period 3 (0–1080) 
Number of previous AEDs
0 18 (27.3%) 
1 24 (36.4%) 
>2 24 (36.4%) 
Number of concomitant AED at baseline
0 27 (40.9%) 
1 34 (51.5%) 
2 5 (7.5%) 2.1. Statistical analysis
Data were analyzed using descriptive statistics. The Chi-square
test (or Fisher’s exact test if the expected frequency was lower than
ﬁve in at least 20% of the cells) was used to compare subgroups
with respect to efﬁcacy, percentage of patients with AEs and
discontinuation for AEs. The Mann–Whitney U test was used to
analyze quantitative variables (time since epilepsy onset and
number of seizures per month). Student’s t-test was used to
compare subgroups with respect to LCM dose changes.
Statistical signiﬁcance was deﬁned at p < 0.05. All statistical




We identiﬁed 66 patients with partial epilepsy who had
received at least one dose of LCM monotherapy, 18 (27.3%) patients
in Group 1 and 48 (72.7%) patients in Group 2. Only 2/66 patients
had learning difﬁculties. Group 2 included 9 patients (13.6%)
directly switched to LCM in the epilepsy monitoring unit or the
emergency room and 39 (59.1%) patients slowly converted to LCM
monotherapy. Mean number of prior AEDs in Group 2 was 2.41
(range 1–9, median 1) and 50% of the patients had previously tried
2 or more AEDs. Reasons for introduction of LCM in patients in
Group 2 were seizure control in 29 (60.4%), tolerability problems in
10 (20.8%), both in 6 (12.5%), and treatment with an AED not
considered to be appropriate for the type of epilepsy in 3 patients.
The demographic and clinical characteristics of the patients are
presented in Table 1.
Median monthly seizure frequency in the 12-month period
prior to LCM monotherapy was 0.7 (SD 9.4; range 0–60) and
mean follow-up in monotherapy was 15.5 months (range 0.5–54
months). Four patients had been seizure-free for at least one year
previous to starting LCM. At the end of the study, 43 (65%)
patients had received LCM monotherapy for more than 12
months. 66) Group 1 (n = 18) Group 2 (n = 48)
11 (61%) 20 (54%)
53.1 (18–90) 48 (16–92)
51.6  23.5 39.6  20
1.5  2.1 8.4  11
10 (55.6%) 25 (52%)
8 (44.4%) 23 (48%)
4 (22%) 12 (25%)
9 (50%) 20 (42%)
11 (61%) 28 (58%)
1.5 (1–60) 2 (0–180)








Mean monthly seizure frequency before and during treatment with LCM.
Mean monthly seizure frequency Group 1 Group 2 p-valuea
Baseline 1.9  4.6 4.4  10.6 0.500
6 months 0.2  0.6 1.3  5.2 0.642
12 months 0.1  0.4 1.5  5.7 0.757
p-valueb <0.001 <0.001
Values as presented as mean  SD.
a p-value for comparison between groups.
b p-value for changes vs. baseline.
B.G. Gira´ldez et al. / Seizure 29 (2015) 119–122 121Overall, the mean maintenance dose of LCM in monotherapy
was 252.7 mg/day (range 100–600). The dose of LCM was
signiﬁcantly higher in patients from Group 2 than in patients
from Group 1 (270.8 vs. 204.2 mg; p = 0.003).
3.2. Efﬁcacy
Forty-two (63.6%) patients remained seizure-free in mono-
therapy during all the follow-up. A proportion of patients achieved
seizure-freedom after reaching the maintenance dose following
dosage adjustments: the seizure-free rates at 6 and 12 months on
the maintenance dose were 77.6% and 72.3%, respectively.
Mean seizure frequency reduction for the overall group was 74.8%
at 6 months and 75.6% at 12 months (p < 0.001). Ten (15%) patients
discontinued treatment with LCM monotherapy (6 due to lack of
efﬁcacy, 3 due to side effects and 1 due to personal preference). The
one-year retention rate was 89.4% [IC95 (76.9–96.5%)].
3.2.1. Naı¨ve vs. non-naı¨ve treatment groups
Seizure-free rates were 72.2% (13/18) for Group 1 and 60.4%
(29/48) for Group 2 for the complete follow-up period (p = 0.375).
Neither seizure-free rates (Fig. 1) nor seizure frequency reduction
(Table 2) were found to be statistically different between the two
groups at 6 and 12 months. One-year retention rates were 91.7% for
Group 1 and 88.6% for Group 2 (p = 1.00).
3.2.2. Patients with previous lack of seizure control
In 35 patients from Group 2, LCM was started because of
uncontrolled seizures despite previous treatment with at least one
AED. Mean number of previous AEDs was 2.2 (range 1–9) and 51.4%
of patients had been treated with 2 or more drugs. Median monthly
seizure frequency in this group was 1 (range 0.3–60) and mean
follow-up 16.9 months (range 0.5–54). In total, 54.3% (19/35)
remained seizure-free since the onset of LCM monotherapy. At 6 and
12 months seizure-free rates were 66.7% (20/30) and 65.4% (17/26),
respectively, and signiﬁcant reductions in mean seizure frequency
were recorded (80.1% and 80.2%; p < 0.001). The retention rate at 12
months was 84.2% [IC95 (65.1–95.6%)]. In total 8 withdrawals were
recorded, mainly due to lack of efﬁcacy (6/35; 17.1%).
3.3. Tolerability
Fifteen of 66 patients (22.7%) reported mild to moderate side
effects (Table 3); the most common side effects were somnolence/
fatigue (7.5% of patients) and dizziness (6.1% of patients). Three
patients (4.5%) discontinued treatment due to adverse events
(intense fatigue = 1, dizziness = 1, pruritus and insomnia = 1), two
of them in the ﬁrst month of treatment. No differences wereFig. 1. Percentage of patients with LCM as initial monotherapy (Group 1) or
switched (Group 2), who remained seizure-free since the onset of LCM
monotherapy (complete follow-up) and at 6 and 12 months after reaching a
maintenance dose following dosage adjustments.observed between Groups 1 and 2 regarding the type of side effect
or rate of patients suffering side effects (22.9% vs. 22.7%; p = 1.00).
3.3.1. Tolerability in patients with side effects with previous AEDs
LCM was started in 16 patients because of tolerability problems
with a previous AED. Mean number of previous AEDs in this group
was 2.4 (range 1–9) with 56.2% of the patients having tried at least
2 AEDs. Mean follow-up was 16.7 months (range 0.5–36).
Side effects related to LCM therapy were recorded in only 3
patients (18.8%) and led to discontinuation in 1 patient (fatigue).
4. Discussion
This study investigates a series of patients with partial-onset
seizures on LCM monotherapy as ﬁrst-line or conversion regimen
in clinical practice. Overall, about two-thirds of the 66 patients
included in this study remained seizure-free during the complete
follow-up and a higher percentage achieved seizure-freedom after
reaching a maintenance dose, both at 6 and 12 months, suggesting
that some patients beneﬁt from additional up-titration of the drug
and that the efﬁcacy is maintained over time.
Direct comparisons with the few other published studies
investigating the use of LCM as monotherapy are not feasible due
to differences in patient populations and methodologies. As an
example there is a remarkable difference between our results and
those reported by Wechsler et al. In their LCM monotherapy
conversion clinical trial during the 10-week monotherapy phase,
only 12.9% and 14.4% of the patients receiving LCM 300 or 400 mg/
day remained seizure-free [6]. This difference can be explained at
least in part by the characteristics of the population included in the
trial. Inclusion criteria included a minimum of 2 seizures per 28
days during the 8-week baseline period. Additionally mean time
since ﬁrst diagnosis was 17.1 years and 45.4% of the patients had
tried 3 or more antiepileptic drugs. These patients might not be
considered as eligible for monotherapy in an everyday clinical
setting and, as a consequence, results may not reﬂect the efﬁcacy
proﬁle of the drug in the early stages of epilepsy. In contrast,
Villanueva et al. reported seizure-free rates as high as 86.4% and
86.4% at 6 and 12 months in 22 patients who were successfully
converted to LCM monotherapy after having failed to control
seizures with a ﬁrst or second AED [8]. Among other factors,Table 3
Side effects associated with LCM monotherapy.
Side effecta Total, n (%) Group 1, n (%) Group 2, n (%)
Somnolence/fatigue 5 (7.5) 3 (16.6) 2 (4.1)
Dizziness 4 (6.1) 2 (11.1) 2 (4.1)
Headache 3 (4.5) 1 (5.5) 2 (4.1)
Gastrointestinal distress 3 (4.5) 1 (5.5) 2 (4.1)
Tremor 1 (1.5) 0 1 (2)
Insomnia 1 (1.5) 1 (5.5) 0
Pruritus 1 (1.5) 1 (5.5) 0
a Some patients reported more than one side effect.
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the last 6 months at the 12-month visit in the study by Villanueva
et al.) may signiﬁcantly account for the lower seizure-free rate
found in the present study in the subgroup of 35 patients in whom
LCM was added because of lack of seizure control with previous
AEDs (66.7% and 65.4% at 6 and 12 months). Independently of the
mentioned differences between theses studies, altogether these
data suggest that better results in terms of efﬁcacy are obtained
when LCM monotherapy is used in a less refractory setting [8].
We did not ﬁnd signiﬁcant differences in terms of efﬁcacy
between naive-treatment patients and those previously exposed to
other AEDs although seizure-free rates were numerically higher in
patients with recently diagnosed epilepsy. Signiﬁcant lower doses of
LCM in Group 1 are likely to be inferred as it includes an easier to treat
population. Given the pragmatic approach used in this study,
differences in LCM doses may also reﬂect physician’s preferences
such as the use of higher initial drug doses before switching to
monotherapy in patients who have failed a previous AED. Aside from
the small sample size precluding statistical signiﬁcance, lack of
differences may also be related to the clinical characteristics of the
patients included in the latter group. The majority (70.8%) of these
patients had failed a maximum of only two previous drugs, including
a small percentage of patients with tolerability problems and seizure-
free before LCM had been added. Actually, in our routine clinical
practice, monotherapy is usually not attempted in patients with more
refractory epilepsy. Accordingly, in an audit of levetiracetam (LEV)
monotherapy, Stephen et al. [9] found that seizure freedom was more
likely in those patients who switched after failing their 1st or 2nd AED
compared to later in the treatment schedule (60.9 vs. 13.3%), and
similar to those with LEV as a ﬁrst monotherapy (54.4%).
In this study LCM was generally well tolerated and associated with
only mild to moderate side effects, even in patients who had failed
previous AEDs because of tolerability problems. Only a small
proportion of patients (4.5%) discontinued treatment with LCM
because of side effects. Postmarketing studies investigating adjunctive
LCM reported much higher rates of AE ranging from 33 to 61%
[4,10,11] and discontinuation rates from 9 to 22% [7,10,11].
Monotherapy with a single AED has been related with a lower risk
of toxicity and a reduction in the number of adverse events [12].
Interestingly, we did not ﬁnd signiﬁcant differences in the rate or
proﬁle of AEs between patients naive to AED therapy and those
converted to monotherapy. This could be explained by the initial low
doses and ﬂexible titration schedule employed in the present study,
which may have improved tolerability even in patients already
established in AED therapy. In the Wechsler et al. study up to 84.5% of
the patients reported side effects, a safety proﬁle similar to that
observed in LCM add-on regulatory trials. The highest incidence of AEs
occurred during the titration phase while patients were still receiving
background AEDs. However, not only polytherapy but also the higher
initial LCM doses of 200 mg/day and ﬁxed titration to the randomized
dose in this study can explain the high incidence of AE [6]. In our series,
and in agreement with previous studies, the commonest side effects
were somnolence/fatigue, dizziness and headache.
The present study is limited by its retrospective nature and, as
already mentioned, the small sample size of the subgroups that
may preclude ﬁnding differences of efﬁcacy and tolerability
between naive-treatment patients and those previously exposed
to other AEDs. However, the value of our study includes the
existence of long-term follow-up data and a real-life picture of the
performance of LCM monotherapy in routine clinical practice,
including its use as a ﬁrst-line regimen.
5. Conclusions
In this series, the outcome of patients treated with LCM
monotherapy is encouraging. More than two-thirds of the patientsremained seizure-free since the beginning of treatment and an
additional proportion of patients achieved long-term seizure
freedom following dosage adjustments. Tolerability was good
and only a small proportion of patients discontinued LCM because
of tolerability problems. Our experience suggests that LCM
monotherapy, whether as ﬁrst-line or after conversion, may be a
valuable treatment option for patients with focal epilepsy.
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